bioRxiv · 10.1101/2020.08.03.234872
Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease
Abstract
This paper presents the design and study of a first-in-class cyclic peptide inhibitor against the SARS-CoV-2 main protease (Mpro). The cyclic peptide inhibitor is designed to mimic the conformation of a substrate at a C-terminal autolytic cleavage site of Mpro. Synthesis and evaluation of a first-generation cyclic peptide inhibitor reveals that the inhibitor is active against Mpro in vitro and is non-toxic toward human cells in culture. The initial hit described in this manuscript, UCI-1, lays the groundwork for the development of additional cyclic peptide inhibitors against Mpro with improved activities.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kreutzer, A. G., Krumberger, M., Parrocha, C. M. T., Morris, M. A., Guaglianone, G., Nowick, J. S.. 2020-08-03. Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease. https://doi.org/10.1101/2020.08.03.234872
Cite the original work for its findings. Save a collection to share your selection of sources.